Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia
Dawn I. Velligan(The University of Texas at San Antonio Health Science Center), Judith Jaeger(Albert Einstein College of Medicine), David P. Walling(Collaborative Neuroscience Network), Robert Riesenberg, Ronald Brenner(Neurobehavioral Research (United States)), Franco Sicuro, Dennis Sweitzer(AstraZeneca (United States)), Charles Merideth, Adonis Sfera(Patton State Hospital)
Cited by 36
Related Papers
Self-report measures of medication adherence behavior: recommendations on optimal use
|Translational Behavioral Medicine|2015|832
Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials
|The Lancet|2018|780
Beyond hypofrontality: A quantitative meta‐analysis of functional neuroimaging studies of working memory in schizophrenia
|Human Brain Mapping|2005|622